Lilly acquires Adverum Biotechnologies

Eli Lilly and Company has acquired Adverum Biotechnologies, bolstering its position in the gene therapy field. The acquisition, completed in December 2025, reflects Eli Lilly’s strategy to capitalize on Adverum's promising gene therapy candidate aimed at treating wet age-related macular degeneration (wet AMD), a major cause of vision loss.

Eli Lilly agreed to pay $3.56 per share to acquire Adverum and take it private. Additionally, the transaction includes contingent value rights (CVRs) allowing former shareholders to receive additional payouts contingent upon achieving specific developmental milestones. The primary asset, known as ixoberogene soroparvovec (Ixo-vec), is designed to be a one-time treatment that could significantly reduce the treatment burden for patients, contrasting with current therapies that involve frequent eye injections.

The acquisition is strategically significant for Eli Lilly as it seeks to expand its gene therapy portfolio. Ixo-vec has demonstrated strong potential, with positive interim data from the Phase 2 LUNA study. The subsequent ARTEMIS Phase 3 trial reached full enrollment faster than anticipated, with crucial top-line results expected by early 2027. This development is intended to position Eli Lilly more prominently in ophthalmology, complementing its existing R&D initiatives.

In a broader market context, this acquisition highlights the intensifying competition in the biotech sector as major firms vie for groundbreaking treatments for chronic conditions. Eli Lilly's move into the ophthalmology arena through Adverum’s technology could differentiate it from competitors relying on standard anti-VEGF therapies. Success with Ixo-vec would likely accelerate similar strategic acquisitions in the industry as companies seek to integrate transformative therapies into their portfolios.

Looking ahead, Eli Lilly's integration of Adverum’s operations and pipeline will be closely watched. Key milestones include the anticipated data outcomes from the ARTEMIS trial, which will inform future regulatory engagements and the ultimate commercial rollout. The therapeutic landscape could see significant shifts if Ixo-vec proves to be as effective as early studies suggest.